American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Regencell Bioscience Holdings Ltd (RGC)

$5.72 +1.78% NASDAQ: RGC · 15-min delayed

Public · NASDAQ: RGC
10 employees

Visit website Follow

$9.9BMarket cap

-$3.6MNet income

10Employees

RGCNASDAQ

2021IPO

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: RGC
Employees: 10
IPO date: Jul 16, 2021
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: RGC Nasdaq
SEC CIK: 1829667
SIC: 2833 Medicinal Chemicals & Botanical Products

Embed this company’s badge

Show Regencell Bioscience Holdings Ltd’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/regencell-bioscience-holdings-ltd/"><img src="https://americancompanies.com/badge/regencell-bioscience-holdings-ltd.svg" alt="Regencell Bioscience Holdings Ltd — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Regencell Bioscience Holdings Ltd and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$3.6M
Total assets: $5.8M
Market cap: $9.9B
Operating margin: 8.6%
Net margin: 3.6%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2013

FY2014

FY2015

FY2016

FY2017

Revenue Net income

FY 2017

Financial statements

Income statement

Revenue: $3.2B
Operating expenses: $2.9B
Operating income: $271.7M
Income tax: $101.6M
Net income: $112.3M
EPS (basic): $0.72
EPS (diluted): $0.72

Balance sheet

Total assets: $2.8B
Current assets: $463.3M
Total liabilities: $3.7B
Current liabilities: $561.4M
Shareholders’ equity: -$855.8M

Cash flow

Operating cash flow: $409.9M
Investing cash flow: -$410.6M
Financing cash flow: -$17.0M
Net cash flow: -$17.7M

Statements via Polygon.io (SEC filings)

NASDAQ: RGC

$5.72 +1.78%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.78 $52.88

52-week range

Market cap: $9.9B
P/E ratio: 7.9
EPS (diluted): $0.72
Dividend yield: 15.38%
Shares outstanding: 1.7B
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 16, 2021

Regencell Bioscience Holdings Ltd (RGC) Stock Price

Reported a net loss of $3.6M.
Revenue grew 4% from FY2013 to FY2017.
Trading 89% below its 52-week high.
Pays a dividend yielding about 15.38% annually.
Valued at a price-to-earnings (P/E) ratio of 7.9.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Regencell Bioscience Holdings Ltd.

Write a review

Newsroom

News about Regencell Bioscience Holdings Ltd

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire Inc. · 2026-06-22 · negative FSK DEADLINE NOTICE: ROSEN, A RANKED AND LEADING FIRM, Encourages FS KKR Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FSK GlobeNewswire Inc. · 2026-06-22 · negative REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC GlobeNewswire Inc. · 2026-06-22 · negative RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026 GlobeNewswire Inc. · 2026-06-21 · negative SRAD IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sportradar Group AG Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SRAD GlobeNewswire Inc. · 2026-06-18 · negative REGENCELL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC GlobeNewswire Inc. · 2026-06-18 · negative

News & sentiment via Polygon.io

FAQ

Regencell Bioscience Holdings Ltd: frequently asked questions

Is Regencell Bioscience Holdings Ltd an American company?

Regencell Bioscience Holdings Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Regencell Bioscience Holdings Ltd publicly traded?

Yes — Regencell Bioscience Holdings Ltd is a publicly traded company. Its stock trades under the ticker symbol RGC on the NASDAQ.

What does Regencell Bioscience Holdings Ltd do?

Regencell Bioscience Holdings Ltd is an American Pharmaceuticals company in the Health & Beauty sector.

Explore